Navigation Links
Sangamo BioSciences to Present at the 2007 BIO InvestorForum
Date:10/3/2007

RICHMOND, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Philip Gregory, D.Phil., Sangamo's vice president of research, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:45pm (PT) on Wednesday, October 10, 2007 at the BIO InvestorForum in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... 11 Alimera Sciences Inc., a privately held,biopharmaceutical ... of prescription ophthalmic pharmaceuticals, today reported,that enrollment has ... safety and efficacy,of Iluvien(TM) in patients with bilateral ... , The ...
... Shareholder Value , , CHICAGO, Dec. ... affiliates, of nearly 29% of the outstanding shares of common stock ... it had delivered a letter to Avigen,s Board of Directors expressing ... value. , , The ...
... today that they continue to penetrate and build market share in ... energy by working with companies like Southwest Windpower, MiaSole, Solyndra, Santur ... ... December 11, 2008 -- DAZ Systems, Inc. , announced today ...
Cached Biology Technology:Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5DAZ Systems, Inc. Thrives in the Clean Energy Industry 2DAZ Systems, Inc. Thrives in the Clean Energy Industry 3
(Date:4/17/2014)... infection , Respiratory syncytial virus (RSV) is ... generating life-threating illness in very young and elderly ... RSV enters host cells through the fusion protein ... Small interfering peptides that prevent bundle formation limit ... highly susceptible to degradation. In this issue of ...
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... patients with epilepsy carry might enable doctors to better ... seizures, suggest basic findings by researchers at the Duke ... the University College London. Patients often undergo a lengthy ... of anti-epilepsy drugs appropriate for them. , The researchers ...
... lymphocytic leukemia (B-CLL),is the most common leukemia in ... mature B lymphocytes in the blood, bone,marrow, and ... early stages,of disease, B-CLL is the result of ... normal B cell death (apoptosis). Livio,Trentin and colleagues ...
... expert manipulators when it comes to co-opting their host's ... from the vast repertoire of proteins and mechanisms dedicated ... like HIV have evolved myriad ways of redirecting that ... eukaryotes have three types of RNA polymerases, each charged ...
Cached Biology News:Gene variations explain drug dose required to control seizures 2Gene variations explain drug dose required to control seizures 3Gene variations explain drug dose required to control seizures 4An HIV Protein Plays a Surprising Role in Gene Activation 2An HIV Protein Plays a Surprising Role in Gene Activation 3